L eft ventricular (LV) remodeling after myocardial infarction is considered to set the stage for heart failure and premature death by transformation of both necrotic and peri-infarct tissue. 1 The dogma of irreversible loss of tissue was challenged with the observation of replicating human cardiac muscle cells in a viable syncytium. 2, 3 Although animal experiments using cell transplantation techniques (eg,
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fetal cardiomyocytes or skeletal myoblasts) have succeeded in reconstituting heart muscle, these cells fail both to completely integrate structurally and to display characteristic physiological function. 4 -6 Conversely, bone marrow-derived pluripotent adult stem cells not only are capable of tissue differentiation [7] [8] [9] but also are likely to regenerate myocardium by inducing myogenesis and angiogenesis, as shown by improved cardiac function in animals and preliminary human studies. 10 -16 Interestingly, there is mounting evidence that pluripotent cells enhance myocardial restoration regardless of their route of administration either by intramyocardial injection, by intracoronary and intravenous infusion, or even by mobilization with cytokines. Mobilization of a critical number of pluripotent cells is an interesting concept, 11 given that 5ϫ10 6 circulating stem cells can be removed from the peripheral blood by apheresis of normal human donor blood after several days of granulocyte colony-stimulating factor (G-CSF) stimulation. 17 Recent observations, however, have challenged myocardial regeneration in favor of direct cytokine effects.
In this context, we tested both the safety and impact of G-CSF in the setting of human myocardial infarction in conjunction with primary percutaneous coronary intervention (PCI) and abciximab 18 in a randomized study with serial assessment of LV function and metabolism after 1 and 4 months and coronary morphology at 6 months.
Methods

Patients and PCI
FIRSTLINE-AMI was initiated in April 2003 and set up to recruit 50 consecutive patients with acute ST-elevation myocardial infarction (STEMI) subjected to primary PCI with stenting and abciximab administration according to recent guidelines 18 ; after successful reperfusion, patients were randomized by use of the closed-envelope method in 1:1 allocation (with 25 subjects per group) to 10 g/kg G-CSF over a period of 6 days in addition to standard care or to standard postinterventional care alone.
Patients between 18 and 65 years of age and with first STEMI comprising Ն3 of 12 ECG leads were eligible; cardiogenic shock (defined as systolic blood pressure Ͻ80 mm Hg requiring intravenous pressors or intra-aortic balloon counterpulsation), major bleeding requiring blood transfusion, a history of leukopenia, thrombocytopenia, hepatic or renal dysfunction, evidence of malignant disease, or unwillingness to participate were criteria for exclusion.
After successful recanalization of the infarct-related artery by facilitated PCI using abciximab and modern bare-metal stents, randomization by the closed-envelope method was initiated. Both G-CSF recipients and control subjects were monitored continuously for arrhythmogenic or hemodynamic events over a period of 6 days and followed up for 6 months. The pilot study, using PROBE design with open-label application of G-CSF but blinded evaluation by expert readers unaware of patient group assignment (flow chart in online-only Appendix; see http://circ.ahajournals.org/cgi/content/ full/CIRCULATIONAHA.105.541433/DC1), was approved by the Institutional Ethics Committee and the Ethics Review Board of the University of Rostock, Germany, and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient.
Stem Cell Mobilization
Within 89Ϯ35 minutes of successful PCI, patients were randomly assigned to subcutaneous G-CSF (Amgen GmbH) at a dose of 10 g/kg body wt over a period of 6 days in addition to standard care or to standard care alone, including aspirin, clopidogrel, ACE inhibitors, ␤-blockers, and statins in appropriate doses. Quantification of total white blood cells (WBCs) and CD34ϩ mononuclear blood stem cells (MNC CD34ϩ ) by flow cytometry was monitored from whole blood directly sampled before PCI and at days 4, 5, and 6 after PCI; parameters of blood viscosity were determined at baseline and at 6 and 35 days. 19 
Flow Cytometry (MNC CD34؉ Enumeration)
Stem cell concentration in peripheral blood was obtained according to the IGLD protocol 20 ; 100 L of peripheral blood (anticoagulant K3-EDTA) was incubated for 15 minutes on ice with both pretitered CD45-fluorescein-conjugated (clone 2D1) and CD34-phycoerythrin-conjugated (clone 8G12) monoclonal antibody of 10 L each. Similarly, control samples were incubated with fluorochromeconjugated isotypic control antibodies (clone X40), all purchased from Becton-Dickinson. After incubation, erythrocytes were lysed by resuspension of the samples in 2 mL FACS lysing solution for 8 minutes at room temperature. Samples were centrifuged for 10 minutes at 200g and 4°C; cells were washed 2 times with PBS at pH 7.2 and then measured in a FACSort flow cytometer (Becton Dickinson).
By use of the CellQuest Software package, at least 50 000 cells were measured in samples incubated with CD45 and CD34, and 10 000 cells were counted in isotypic control samples. Stem cells were counted by a gating strategy based on a combination of specific CD45 and side-scatter patterns of CD34ϩ cells, allowing exact calculation of the percentage of CD34-positive leukocytes down to 0.1%. The number of MNC CD34ϩ per L was derived from the relation of CD34ϩ cells and WBCs of the blood sample ( Figure 1 ).
Angiography and Quantitative Coronary Arteriography
Coronary and biplane LV angiograms were obtained according to standard acquisition guidelines both with initial PCI and at followup. Baseline ejection fraction (LVEF) and volumes were calculated by use of the area-length method 21 ; coronary angiograms were evaluated for binary restenosis, (in-stent) late lumen loss, and minimal lumen diameter of the target lesion. Offline quantitative coronary arteriography was performed from digital cineangiograms by use of a MEDOS workstation and a validated edge-detection algorithm. 22 Identical unforeshortened coronary projections were used and analyzed at baseline and at 6 months. Restenosis at follow-up was defined as a diameter stenosis of Ͼ50% within the stent Ϯ5 mm.
Echocardiography and Dobutamine Challenge
Four days, 35Ϯ2 days, and 121Ϯ7 days (4 months) after facilitated PCI, resting and low-dose dobutamine echocardiography was performed to assess viable myocardium. In brief, dobutamine was infused at doses of 5 and 10 g · kg Ϫ1 · min Ϫ1 in 5-minute stages on days 4Ϯ1 and 35Ϯ2 and after 4 months of PCI in conjunction with 2D echocardiographic imaging using a phased-array electronic ultrasound system in 4 standard views (parasternal long-axis and short-axis views and apical 4-and 2-chamber views) while 12-lead ECG and blood pressure were recorded continuously. Global function and regional LV wall motion were digitized by use of an ATL HDI 5000 ultrasound system and analyzed according to the Standards of the American Society of Echocardiography 23 ; both intraobserver and interobserver variability of independent expert readers blinded to treatment allocation was low, with correlation coefficients of 0.96 and 0.94, respectively. For quantification of wall motion, the standardized 16-segment model was used, integrating segmental wall motion scores of 1ϭnormal, 2ϭhypokinesis, 3ϭakinesis, and 4ϭdyskinesis 23 ; wall motion score index (WMSI) was calculated as the sum of the scores of the segments divided by the number of the segments evaluated. Segmental wall thickening in the infarct territory encompassing the central area of dysfunction by wall motion analysis was assessed from the relation of average end-diastolic and systolic wall thicknesses. Any possible effort was made to compare identical segments over time by adherence to recent expert recommendations. 24 Early diastolic mitral flow velocity deceleration time was measured as a parameter of diastolic function correlating closely with LV end-diastolic pressure. 25 
F-Deoxyglucose-Positron Emission Tomography
Baseline and follow-up 18 F-deoxyglucose-positron emission tomography ( 18 FDG-PET) imaging was performed in all 50 patients 5Ϯ1 and 128Ϯ6 days (4 months) after index STEMI by use of a whole-body scanner (Philips, IRIX Gamma PET III). Two hours after oral administration of 250 mg acipimox and 30 minutes after 50 g oral glucose, 350 to 470 MBq 18 FDG was administered 26, 27 ; 2 diabetic patients were subjected to hyperinsulinemic euglycemic clamping. 26 Image acquisition was started 40 minutes after 18 FDG administration, and standardized quantitative image analysis was performed in a polar map display of the mean 18 FDG uptake signal intensity in the 3 respective myocardial perfusion territories.
Data Collection and Follow-Up Examination
Clinical and laboratory data were collected prospectively, and follow-up visits were scheduled at 35 days and 4 months; standard C-reactive protein and fibrinogen measurements were accompanied by ELISA for interleukin-6 and transforming growth factor-␣ (Biosource Diagnostics). Specific attention was paid to potential signs or symptoms of coronary events or arrhythmia. Low-dose dobutamine echocardiography was repeated on day 35 and after 4 months in all patients; 18 FDG-PET studies were executed at 5Ϯ1 days and 4 months after index STEMI. Adherence to medication and 6-month coronary angiography according to the study flow chart were complete (see online-only Appendix).
Statistical Analysis
Continuous variables are presented as meanϮSD; categoric variables were compared by use of 2 or Fisher's exact test. Statistical comparisons between treatment groups were made by repeatedmeasures ANOVA or by paired or unpaired Student's t test if appropriate. Repeated measurements were analyzed by 2-factor ANOVA to evaluate differences across time and between groups encompassing serological and hematological variables as well as morphological and functional echocardiographic parameters; report-ing of the trial results followed established CONSORT guidelines. 28, 29 Statistical computing was performed by use of SPSS (Version 11.5, SPSS Inc.); for all tests, a probability level of PϽ0.05 was considered significant.
Results
Demographics, clinical characteristics, and comorbidity profiles were homogeneous and revealed a typical distribution of risk factors and evidence-based medication ( Table 1 ). Angio- 
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graphic and infarction-related characteristics showed a balanced distribution, including enzyme release and baseline LV function (Table 2 ). Moreover, time from onset of symptoms to PCI with stent placement was similar, at 299Ϯ101 minutes in the G-CSF group and 304Ϯ111 minutes in control subjects (Pϭ0.86). No complications were associated with acute PCI, and all occluded infarct-related arteries were recanalized and stented with adjunctive abciximab infusion and subsequent clopidogrel loading; TIMI III flow was documented in all patients after PCI. Subcutaneous G-CSF injection was begun 89Ϯ35 minutes after reperfusion. Postinfarction medication was identical in both groups, with an oral intake of 100 mg aspirin, 75 mg clopidogrel, statins, and tailored ACE inhibitors and uptitrated ␤-blocker medication. Four and 5 cases of binary restenosis at 6 months without resting flow limitation (TIMI III flow) were detected in the G-CSF and control groups, respectively; both late lumen loss and minimal lumen diameter were not different between groups (Table 2) . Table 3 demonstrates the effect of G-CSF-induced mobilization of MNC CD34ϩ and total WBCs over time with twicedaily injection of G-CSF (2ϫ5 g/kg). Whereas baseline concentrations of MNC CD34ϩ were similar in both groups before revascularization, G-CSF administration induced a 10-fold increase in MNC CD34ϩ at day 4, a 14-fold increase at day 5, and a 20-fold increase by day 6; control patients revealed only mild spontaneous MNC CD34ϩ liberation in the postnecrosis phase. In parallel, baseline WBCs was mildly elevated at the time of reperfusion in both groups but rose with G-CSF administration in concert with MNC CD34ϩ . Serial ⌬ ST-segment analysis from 12-lead ECG in 12-hour intervals over 6 days revealed no evidence of ST changes suggestive of impaired microcirculation. Although MNC CD34ϩ and WBCs increased markedly during G-CSF administration, parameters of rheology such as serum fibrinogen and blood viscosity were similar at baseline and after 6 and 35 days in both groups. As markers of inflammation, interleukin-6, C-reactive protein, and transforming growth factor-␣ showed a similar pattern in both groups at baseline, at day 6, and after 35 days. There was neither any indication of transiently elevated body temperature or relevant bone pain nor evidence of any adverse (or leukocytoclastic) events. In addition, during 6 days of continuous ECG recording, there was no documentation of increased ventricular ectopic activity or any ventricular tachycardia/fibrillation in either group; 24-hour Holter monitoring at days 9Ϯ2 and 35Ϯ4 and after 4 months †Changes over time are significant at PϽ0.001 by a 2-factor repeatedmeasures ANOVA but not different between treatment groups (test for interaction).
Blood viscosity indicates mPaϫs (milliPascalϫseconds); IL-6, interleukin-6; and TNF-␣, tumor necrosis factor-a.
was uneventful with sinus rhythm in all patients. Morphological and functional parameters at baseline, 35 days, and 4 months are summarized as intergroup and intragroup comparisons in Table 4 .
Parameters of Systolic and Diastolic LV Function
At baseline, all parameters of LV function were similar in both the G-CSF-treated and the control groups (Table 4) . Interestingly, with G-CSF, LV end-diastolic diameter (LVEDD) showed no enlargement over a period of 4 months, whereas LVEDD increased to 58Ϯ4 mm in control subjects and was larger than with G-CSF (Pϭ0.002). Moreover, with G-CSF, mean wall thickness in the infarct territory revealed enhancement by 0.7 mm at day 35 (PϽ0.01), a finding sustained after 4 months (PϽ0.01). Recovery of LVEF with G-CSF was documented at 35 days and over 4 months (PϽ0.01) and eventually measured 54Ϯ8% (PϽ0.001 versus control), whereas no longitudinal improvement was present in control subjects.
Similar to LVEF, resting WMSI revealed partial recovery with G-CSF, from 1.71Ϯ0.22 at baseline to 1.41Ϯ0.25 after 4 months (PϽ0.001), but no change in control subjects ( Figure 2, A and B) . Finally, deceleration time revealed improvement of diastolic function in both groups over 4 months; however, it was more pronounced after G-CSF (PϽ0.01).
Response to Inotropic Challenge
As in resting studies, the response of all LV functional parameters to dobutamine was similar in both groups at baseline (Table 4 ). After 35 days of follow-up, low-dose inotropic challenge enhanced both wall thickness and WMSI in patients treated with G-CSF to 1.18Ϯ0.33 mm wall thickness (PϽ0.001 versus control) and to 1.41Ϯ0.21 WMSI (PϽ0.004 versus control), respectively; improved response to inotropic challenge was sustained both for wall thickness and for WMSI at 4 months (Figure 2, C and D) . Parameters such as LVEDD and LVEF failed to respond to inotropic challenge at 35 days; however, at 4 months, LVEDD was 53Ϯ5 mm with G-CSF and without any sign of progressive enlargement as found in control subjects (PϽ0.001). Similarly, with †Changes over time and between treatment groups are significant at PϽ0.01 by a 2-factor repeated-measures ANOVA.
‡Changes over time, not between treatment groups are significant at PϽ0.01 by a 2-factor repeated-measures ANOVA.
§Changes over time and between treatment groups are significant at PϽ0.001 by a 2-factor repeatedmeasures ANOVA.
G-CSF, LVEF, which was unresponsive to inotropic challenge at 35 days, improved by 4% at 4 months to 59Ϯ7% (PϽ0.001 versus control). Deceleration time was not assessed under inotropic stimulation.
Myocardial Viability
In all patients myocardial 18 FDG uptake was measured by PET both at baseline and at 4 months for longitudinal comparison ( Table 5 ). Patients randomized to G-CSF revealed enhanced mean 18 FDG uptake in the infarct territory after 4 months and greater 18 FDG uptake differential than control subjects ( Table 5 ). The G-CSF group was associated with myocardial 18 FDG uptake enhanced by 11% after 4 months (PϽ0.001 versus baseline) versus none in control subjects (PϽ0.001). The noninfarct territories show no significant changes in either group.
Discussion
This is the first randomized study to use G-CSF to liberate MNC CD34ϩ over the initial 6 days of acute myocardial infarction. The strategy was safe, with no evidence of such adverse events as enhanced inflammation, thrombogenicity, electrical instability, or accelerated restenosis. G-CSF administration with reperfusion over 6 days exposes postischemic human myocardium to approximately 2.8ϫ10 10 mobilized MNC CD34ϩ within 8 days, enhances the chance of populating necrotic areas of the myocardium, and improves regional myocardial function with adrenergic challenge at day 35; with G-CSF, regional improvement was sustained after 4 months and was accompanied by both global and regional functional recovery and enhanced myocardial uptake of 18 FDG in the infarctrelated territory. Conversely, control patients failed to show any mild increase in LVEF at follow-up, as expected with PCI after 5 hours, 30 -32 an observation likely to result from both remote hyperkinesis at baseline and uptitrated oral ␤-blockade at follow-up. Previous studies reported a 4% Figure 2 . A, In control patients, WMSI at rest was unchanged over time, with 1.70Ϯ0.22 at baseline, followed by 1.66Ϯ0.22 after 35 days and 1.65Ϯ0.21 after 4 months. B, After 6 days of G-CSF administration, resting WMSI was similar to control subjects both at baseline (1.71Ϯ0.22) and after 35 days (1.68Ϯ0.25) and revealed recovery to 1.41Ϯ0.25 after 4 months (PϽ0.001 by 2-factor repeated-measures ANOVA and versus control subjects). C, Mild inotropic challenge with low-dose dobutamine (10 g · kg Ϫ1 · min Ϫ1 ) reveals no regional contractile recruitment in control subjects; echocardiographic WMSI was 1.64Ϯ0.21 at baseline, 1.60Ϯ0.23 at 35 days, and 1.61Ϯ0.22 after 4 months of follow-up. D, In patients subjected to 6 days of sustained G-CSF administration, low-dose inotropic challenge improved WMSI from 1.66Ϯ0.23 at baseline to 1.41Ϯ0.21 at 35 days and to 1.35Ϯ0.24 after 4 months (PϽ0.001 by 2-factor repeatedmeasures ANOVA and versus control subjects). WMSIs both at 35 days and after 4 months were significantly enhanced with G-CSF exposure. increase of LVEF at 6 months after PCI 30 and a 3.7Ϯ11% increase with PCI within 4 to 6 hours of coronary occlusion 31 ; similarly, the ADMIRAL trial revealed a 4.1% increase in LVEF after stenting of acute myocardial infarction. 32 None of these studies, however, reported the fraction of patients on ␤-blockers, which was probably low 30 -32 ; conversely, all FIRSTLINE-AMI patients were subject to uptitrated ␤-blockade, were 10 years younger, had single-vessel disease without any chance for ischemic preconditioning, and thus were prone to adverse remodeling (Table 2) , which may in turn explain the lower LVEF without G-CSF at follow-up (Table 3) ; the latter is corroborated by the lack of viability in the infarct-related region of the control group (Table 5) . Interestingly, experimental data in splenectomized mice exposed to G-CSF and stem cell factor have shown enhanced myocardial regeneration after translocation of bone marrow cells. 11 However, despite potential differentiation into cardiomyocytes and vascular cells, 12, [33] [34] [35] recent observations have challenged the potential of bone marrow cells 36, 37 in favor of direct cytokine effects. 38, 39 Another critical issue seems to be the number of circulating stem cells. 10 -12 Although a mild increase of circulating MNC CD34ϩ has been observed with myocardial reperfusion, 40 such an archaic natural defense reflex was not seen outside the setting of acute infarction, as evidenced by measurements in 10 age-matched healthy volunteers with 2.11Ϯ2.09 MNC CD34ϩ /L. The mild spontaneous increase in MNC CD34ϩ in control patients (without G-CSF stimulation; Table 4 ) is supported by additional findings of twice the normal CXCR4ϩ and CD34ϩ cells in human STEMI. 41 Moreover, stromal cell-derived factor 1, required for cell engraftment, is upregulated within 24 hours of myocardial infarction but is not expressed later than 7 days. 42 Nevertheless, it is not understood whether infarction may trigger mobilization of MNC CD34ϩ or whether some cytokines may set the stage for engraftment of circulating CD34/ CXCR4ϩ stem cells in target tissue. With G-CSF, however, bone marrow mobilization enhanced exposure of MNC CD34ϩ to injured reperfused myocardium more than 10-fold over several days. Although intracoronary cell infusion may cause sludge and microemboli in animals, 43 no evidence of impaired rheology or microcirculatory plugging by leukocytes (by elevated serum lactate, liver enzymes, creatine kinase-BB, or creatinine) was documented after G-CSF.
Another potentially beneficial effect may be derived from G-CSF-induced mobilization of leukocytes that are known to play an important role for infarct repair by regulating phagocytosis of necrotic tissue, fibroblast proliferation, and angiogenesis in the experimental reperfusion setting. 38 Accordingly, in FIRSTLINE, the postischemic vascular bed was exposed to approximately 3.1ϫ10 13 total leukocytes over a period of 8 days, enabling an increased number of migrated neutrophils and macrophages to accelerate the healing process of human infarction. Moreover, there is experimental evidence of a G-CSF-dependent protection of cultured cardiomyocytes from apoptotic cell death through upregulation of Bcl-2 and Bcl-xL expression via the G-CSF receptor and the Jak-Stat pathway. In vivo experiments have shown that the G-CSF led to upregulation of G-CSF receptor and activation of the Stat-3 pathway, thereby preventing both cardiomyocyte apoptosis and remodeling after myocardial infarction; favorable effects of G-CSF were documented after 7 days of treatment, without any signs of enhanced cardiac engraftment of mobilized bone marrow cells. 39 In contrast to intracoronary infusion of autologous bone marrow cells, MNC CD34ϩ mobilization by G-CSF differs in various ways: first, MNC CD34ϩ mobilization is noninvasive and requires only subcutaneous injections; second, bone marrow aspiration and preparation is not required (potentially difficult in acute patients); third, repeat catheterization with intracoronary infusion or intramyocardial injections are avoided; fourth, exposure to both G-CSF and to mobilized MNC CD34ϩ begins early after reperfusion in the susceptible phase 39 ; and fifth, exposure of postischemic injured myocardium to mobilized MNC CD34ϩ and leukocytes is sustained over a period of 1 week at concentrations markedly exceeding natural cell mobilization in acute infarction. Whereas intracoronary delivery was enacted as early as 5 to 9 days 14 or 4.3Ϯ1.5 days after the onset of necrosis, 15 6 freshly isolated DiI-labeled human CD34 ϩ cells/100 g rat; for the human setting, this translates into 3ϫ10 8 to 6ϫ10 8 cells on a weight-adjusted basis. Assuming an average blood flow of 0.8 mL · min Ϫ1 · g Ϫ1 , 100 g of injured myocardium was exposed to approximately 2.8ϫ10 10 MNC CD34ϩ and 3.1ϫ10 13 leukocytes with G-CSF stimulation over 8 days (online-only Appendix); blood flow and tissue perfusion in the range of 0.8 mL · min Ϫ1 · g Ϫ1 was previously demonstrated after stenting with abciximab in the clinical setting of acute myocardial infarction. 44 At present, there are no convincing data on body distribution of mobilized stem cells in human infarction. In a nonsplenectomized rat model, systemic delivery of 99m Tclabeled bone marrow-derived stem cells was limited by lung entrapment; a small fraction of less than 2% migrate and colonize infarcted heart. 45, 46 With this conservative (hypothetic) assumption, G-CSF would deliver 2.8ϫ10 8 MNC CD34ϩ over several days, eg, 100-to 1000-fold more MNC CD34ϩ than one-time intracoronary delivery. Nevertheless, this calculation should be used with caution, because the quantity of engrafting MNC CD34ϩ in extracardiac organs is unknown without visualization of stem cells. In the aggregate, the present evidence is too scarce to conclude which method of administration and what number or nature of cells have relevance for potential improvement of cardiac performance.
Limitations
A G-CSF-induced mobilization strategy may have limitations, because no animal model resembles human coronary arteries with multiple unstable coronary plaque in the setting of acute myocardial infarction. 47, 48 Unstable coronary plaque could destabilize from mobilized leukocytes after G-CSF, and elevated WBCs may predict adverse outcomes. 49 The recent MAGIC trial, 50 for instance, reported an unexpectedly high rate of in-stent restenosis in the infarct-related vessel, al-though accelerated restenosis was also found after intracoronary bone marrow-derived stem cells. The controversial impact of G-CSF with (nϭ7) or without cell infusion (nϭ3) on in-stent restenosis, however, was deduced from 10 patients with angiographic follow-up and should be interpreted with caution, considering an expected binary restenosis rate of 16% in 25 FIRSTLINE-AMI patients and a clinical restenosis rate of 19% in the Danish STEMMI trial. 51 Interestingly, patients enrolled in STEMMI and FIRSTLINE-AMI were between 50 and 55 years of age and had single-vessel obstruction, whereas MAGIC included heterogeneous patients even with chronic infarction and incomplete follow-up; moreover, G-CSF was initiated before plaque removal, potentially allowing cytokines and mobilized cells to destabilize a culprit lesion and promote accelerated restenosis. 50 However, with G-CSF given after successful stenting in 65 patients, restenosis was found to be within the expected range. 51, 52 Finally, with abciximab given to all patients, neither impaired coronary microcirculation nor impaired rheology was seen, corroborating the safety profile of G-CSF in hematological patients. 53, 54 Similar to recent experience, 50 inflammatory markers were not enhanced by G-CSF in the setting of infarction, confirming experimental findings without aggravated inflammation in murine infarcted heart. 55 Conversely, enhanced myocardial uptake of 18 FDG over time (versus control subjects) argues not only against potential deleterious effects of elevated MNC CD34ϩ or leukocytes in target tissue but for colonization of metabolically active cells. Although stem cell-derived cardiomyocytes, studied in vitro by patch-clamp techniques, show spontaneous activity, low dV/dT, prolonged action potential duration, and easily inducible triggered arrhythmias, 56 no such arrhythmogenic phenomena were observed during continuous monitoring over 6 days and additional Holter recording on days 9Ϯ2 and 35Ϯ2 and at 4 months, probably because of lateral seeding of pluripotent MNC CD34ϩ rather than formation of islands of cells. In vivo imaging of labeled mobilized MNC CD34ϩ , however, is not feasible, and mechanisms such as transdifferentiation of MNC CD34ϩ or aborted apoptosis of cardiomyocytes are difficult to elucidate in the human setting. Moreover, although transdifferentiation of MNC CD34ϩ has recently been challenged, 36, 37 G-CSF may have direct antiapoptotic potential, 39 may activate prosurvival gene Akt 1 encoding for the Akt protein required to repair infarcted myocardium, 57, 58 or may accelerate the process of healing. 38 At present, however, both the issue of plasticity and direct effects in humans are unresolved and should be subject to further investigation; in fact, MNC CD34ϩ may act via paracrine effects, with delivery of growth factors, which could in turn activate resident progenitor cells or other stem cells (c-kitϩ), eventually promoting tissue repair.
Although all 4 patients with restenosis in the G-CSF group revealed TIMI III flow at 6 months, a potentially inhomogeneous occurrence of in-stent hyperplasia with negative impact on functional recovery may not be fully excluded. In addition, the small trial size, with a strong male preponderance (92%), characterizes the pilot nature with limited power to generalize preliminary findings of functional preservation with G-CSF.
Conclusion
G-CSF after reperfusion of infarcted myocardium seems to be safe and feasible, was correlated with better preservation of ventricular function and less remodeling, and was not associated with aggravated post-PCI restenosis rate. This concept of myocardial preservation warrants further investigation, longer follow-up surveillance, and the scrutiny of multicenter, placebo-controlled trials.
Moreover, echocardiographic assessment of function may have inherent limitations as a result of 2D imaging compared with either radionuclide blood pool imaging or volumetric MRI. With a focus on safety and feasibility, a radiation burden had to be avoided in the pilot phase; however, an upcoming multicenter trial will implement sophisticated MRI. Finally, although open by design, this concept trial used randomization and blinded evaluation; additional trials should implement a double-blinded approach and independent evaluation, considering that the predominant findings are that G-CSF tended to blunt deteriorating cardiac function as seen in control subjects. Thus, the present beneficial effects of G-CSF should not be overemphasized.
